Orodispersible Ticagrelor in Acute Coronary Syndromes

Analgesic drug use in patients with STEMI: Current perspectives and challenges

“…The TASTER study, led by Guido Parodi et al, examined the effectiveness of a new Ticagrelor formulation, an oral dispersible tablet (ODT) that does not require water and quickly releases its components upon swallowing. Despite the lack of significant distinction between the new orally disintegrating tablet (ODT) and the conventional Ticagrelor tablets in terms of platelet inhibition, ODT has a superior safety and convenience advantage, particularly in ambulances ( 12 ).…”

Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report

“…Serum concentration of ledipasvir, ombitasvir, elbasvir, daclatasvir and simeprevir may be increased when combined with ticagrelor and these drugs should not be used in combination ( Zhou et al, 2011 ). The orodispersible formulation of ticagrelor (ODT) has recently been tested in patients with ACS ( Parodi et al, 2021 ). Although ODT could theoretically be absorbed in a large amount by the upper gastrointestinal tract, thus avoiding first-pass metabolism by the liver, the potential beneficial effects in terms of DDI reduction have not been investigated so far ( Parodi et al, 2021 ).…”

“…The orodispersible formulation of ticagrelor (ODT) has recently been tested in patients with ACS ( Parodi et al, 2021 ). Although ODT could theoretically be absorbed in a large amount by the upper gastrointestinal tract, thus avoiding first-pass metabolism by the liver, the potential beneficial effects in terms of DDI reduction have not been investigated so far ( Parodi et al, 2021 ). As a general rule, the administration of orodispersible tablets might be an alternative way through mucosal membrane absorption which minimizes first pass metabolism by the liver and, by consequence, the potential DDIs related to the CYP pathway ( Parodi et al, 2021 ).…”

“…Although ODT could theoretically be absorbed in a large amount by the upper gastrointestinal tract, thus avoiding first-pass metabolism by the liver, the potential beneficial effects in terms of DDI reduction have not been investigated so far ( Parodi et al, 2021 ). As a general rule, the administration of orodispersible tablets might be an alternative way through mucosal membrane absorption which minimizes first pass metabolism by the liver and, by consequence, the potential DDIs related to the CYP pathway ( Parodi et al, 2021 ). Cangrelor, a non-thienopyridine adenosine triphosphate analogue, is a potent intravenous, rapid-acting, reversible P2Y12 receptor antagonist that inhibits platelet activation and aggregation ( Kengreal (cangrelor) [prescribing information], 2015 ).…”

“…Currently available antiviral drug classes were involved in DDI assessment: ribavirin and DAAs such as nonstructural protein (NS) 3/4A protease inhibitors, NS5A direct inhibitors and NS5B polymerase inhibitors. A search was conducted through the webbased engine PubMed in order to identify all peer-reviewed studies relevant to the topic published within the last 5 years (2016)(2017)(2018)(2019)(2020)(2021). In addition, information from the Summary of Product Characteristics approved by the European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) regulatory authorities were used.…”